Entero Therapeutics, Stock Performance
| ENTO Stock | 0.66 0.04 6.45% |
Entero Therapeutics, holds a performance score of 9 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -0.56, which means possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Entero Therapeutics, are expected to decrease at a much lower rate. During the bear market, Entero Therapeutics, is likely to outperform the market. Use Entero Therapeutics, value at risk, as well as the relationship between the skewness and day median price , to analyze future returns on Entero Therapeutics,.
Risk-Adjusted Performance
9 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Entero Therapeutics, are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, Entero Therapeutics, displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:20 | Last Split Date 2023-12-18 |
1 | Roby Zomer Bought 76 percent More Shares In Argent BioPharma | 10/24/2024 |
2 | Integrated BioPharma Reports Results for its Quarter Ended September 30, 2024 | 11/13/2024 |
3 | Trumps FDA pick Makary boosts BioPharma confidence, says BMO | 11/25/2024 |
4 | Can-Fite BioPharma Receives Buy Rating from D. Boral Capital | 12/05/2024 |
5 | Jefferies Financial Group Begins Coverage on Mereo BioPharma Group | 12/06/2024 |
6 | ABVC BioPharma Secures 200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling 546,000 From Three Partners | 12/11/2024 |
7 | Kiromic BioPharma Reports 32 percent Decrease in Tumor Volume Eight Months Post-Treatment in Fourth Patient Enrolled in Deltacel-01 | 12/12/2024 |
8 | Tanvex BioPharma, Inc.s last weeks 10 percent decline must have disappointed retail investors who have a significant stake | 12/13/2024 |
9 | Mereo BioPharma Group plc Shares Down 1.9 percent Heres Why | 12/19/2024 |
10 | Quantum BioPharma Diversifies Treasury with the Purchase of USD 1,000,000 of Bitcoin and ... | 12/20/2024 |
11 | Aytu BioPharma, Inc. Is About To Turn The Corner | 12/27/2024 |
12 | Why Mereo BioPharma Is One of the Best Biotech Penny Stocks to Invest in Now | 12/30/2024 |
13 | Argent BioPharma Ltd. Placing to Raise US4,500,000 | 01/06/2025 |
| Begin Period Cash Flow | 1.4 M |
Entero |
Entero Therapeutics, Relative Risk vs. Return Landscape
If you would invest 42.00 in Entero Therapeutics, on October 9, 2024 and sell it today you would earn a total of 24.00 from holding Entero Therapeutics, or generate 57.14% return on investment over 90 days. Entero Therapeutics, is currently generating 1.1382% in daily expected returns and assumes 9.4172% risk (volatility on return distribution) over the 90 days horizon. In different words, 83% of stocks are less volatile than Entero, and 78% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Entero Therapeutics, Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Entero Therapeutics,'s investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Entero Therapeutics,, and traders can use it to determine the average amount a Entero Therapeutics,'s price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1209
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ENTO | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 9.42 actual daily | 83 83% of assets are less volatile |
Expected Return
| 1.14 actual daily | 22 78% of assets have higher returns |
Risk-Adjusted Return
| 0.12 actual daily | 9 91% of assets perform better |
Based on monthly moving average Entero Therapeutics, is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Entero Therapeutics, by adding it to a well-diversified portfolio.
Entero Therapeutics, Fundamentals Growth
Entero Stock prices reflect investors' perceptions of the future prospects and financial health of Entero Therapeutics,, and Entero Therapeutics, fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Entero Stock performance.
| Return On Equity | -0.15 | ||||
| Return On Asset | -0.27 | ||||
| Current Valuation | 66.34 M | ||||
| Shares Outstanding | 3.25 M | ||||
| Price To Book | 0.07 X | ||||
| EBITDA | (15.74 M) | ||||
| Net Income | (15.79 M) | ||||
| Total Debt | 826.84 K | ||||
| Book Value Per Share | 7.99 X | ||||
| Cash Flow From Operations | (12.38 M) | ||||
| Earnings Per Share | (11.04) X | ||||
| Market Capitalization | 1.11 M | ||||
| Total Asset | 6.88 M | ||||
| Retained Earnings | (184.33 M) | ||||
| Working Capital | 1.82 M | ||||
About Entero Therapeutics, Performance
By examining Entero Therapeutics,'s fundamental ratios, stakeholders can obtain critical insights into Entero Therapeutics,'s financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Entero Therapeutics, is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 6 K | 6.3 K | |
| Return On Tangible Assets | (2.73) | (2.87) | |
| Return On Capital Employed | (3.79) | (3.60) | |
| Return On Assets | (2.07) | (2.17) | |
| Return On Equity | (5.04) | (5.29) |
Things to note about Entero Therapeutics, performance evaluation
Checking the ongoing alerts about Entero Therapeutics, for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Entero Therapeutics, help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Entero Therapeutics, is way too risky over 90 days horizon | |
| Entero Therapeutics, has some characteristics of a very speculative penny stock | |
| Entero Therapeutics, appears to be risky and price may revert if volatility continues | |
| Entero Therapeutics, has high likelihood to experience some financial distress in the next 2 years | |
| Entero Therapeutics, was previously known as FWBI Old and was traded on NASDAQ Exchange under the symbol FWBI. | |
| Net Loss for the year was (15.79 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Entero Therapeutics, generates negative cash flow from operations | |
| Entero Therapeutics, has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: Argent BioPharma Ltd. Placing to Raise US4,500,000 |
- Analyzing Entero Therapeutics,'s financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Entero Therapeutics,'s stock is overvalued or undervalued compared to its peers.
- Examining Entero Therapeutics,'s industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Entero Therapeutics,'s management team can have a significant impact on its success or failure. Reviewing the track record and experience of Entero Therapeutics,'s management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Entero Therapeutics,'s stock. These opinions can provide insight into Entero Therapeutics,'s potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Entero Therapeutics,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Entero Stock, please use our How to Invest in Entero Therapeutics, guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entero Therapeutics,. If investors know Entero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entero Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Entero Therapeutics, is measured differently than its book value, which is the value of Entero that is recorded on the company's balance sheet. Investors also form their own opinion of Entero Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Entero Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entero Therapeutics,'s market value can be influenced by many factors that don't directly affect Entero Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entero Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Entero Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entero Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.